Enough of what you can’t do online! This has been the mantra at MM&M in the past few weeks, and the brief for this month’s Patient Marketing Report.
As online grows, will ads take notice?
January 15, 2010
5:31 pm
Data from Nielsen show that while 99% of video in the US is viewed on traditional TV, DVR and online video use is growing fast. Is getting ads in front of those consumers as important as ads to traditional viewers?
More than a year has elapsed since the Obama administration first promised a more transparent government, but all we have seen at the FDA is an elongated public input gathering process by the Transparency Task Force on the expectations of the agency’s numerous diverse constituencies.
New staff puts PDUFA goals back on track, Jenkins says
January 15, 2010
6:00 pm
A two-year hiring push at the FDA’s Center for Drug Evaluation and Research (CDER) has added enough new staff to bring itself back on track with meeting Prescription Drug User Fee Act (PDUFA) goals, according to Office of New Drugs (OND) director John Jenkins.
WLF backs Allergan off-label suit
January 15, 2010
7:34 pm
Washington Legal Foundation (WLF) and three patient advocacy groups have filed a friend of the court brief in the District of Columbia federal court supporting a request by Allergan for a preliminary injunction to block the FDA from enforcing regulations and policies prohibiting the company from providing information to healthcare providers on an off-label Botox.
So much of the discussion around pharma and social media focuses on what you can’t do. Gilead Sciences, Novartis, UCB, Shire and Bayer provide examples of what can be done. Ben Comer reports